MEDIA

Media coverage - Business News Australia

December 2024 - Rhythm announced it was acquiring the Genetype business and assets to create a diversified oncology business with significant growth potential. The Genetype business is a world leader in genetic-integrated risk assessment that offers population level predictive risk testing for a range of cancers and other serious and common diseases. The ability to quantify risk of disease using polygenic risk scores and clinical factors supports Rhythm's goal of detecting disease earlier in a uniquely personal manner.

Read the news coverage here: https://tinyurl.com/mrs4chw2

Media coverage - Stockhead

December 2024 - Rhythm announced to the market that we had attained all key milestones for 2024. Read the subsequent media coverage in Stockhead here: https://tinyurl.com/y7pbbr5r

Media coverage - Small Caps

October 2024 - We announced to the market that preliminary testing of 200 patient serum samples using the new multiplex Alpha antibody kit revealed superior analytical results compared to tests performed on the first-generation product. Read more here: https://tinyurl.com/5est5upc

Interview - MTPConnect Podcast

In June 2023 Rhythm Biosciences Chief Commercial Officer Elena Deak attended BIO in Boston where she spoke with Caroline Duell from MTPConnect.

"Back in June, MTPConnect joined the Australian delegation at BIO in Boston and organised several activities to showcase Australia’s fast-growing life sciences sector to the international biotech industry.

In part one of this BIO episode, host Caroline Duell heads to the Australian Pavilion at the Boston Convention Centre to catch up with Australian companies, entrepreneurs and researchers looking to do business at BIO and drive collaborations, partnerships and investments."

For more on MTP Connect and the podcast visit: https://www.mtpconnect.org.au/mtpconnectpodcast

Elena's Interview starts at 19:05. To listen, click play: